Filter posts

PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine …

Senate Has the Power to Expand Access to Medication for Opioid Addiction

BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the …

Changes to the Pandemic and All Hazards Preparedness Act Are Essential to Saving Lives in Disasters

Writing for The Hill, Dr. Robert Kadlec, Assistant Secretary for Preparedness and Response for the …

Pfizer CEO: How the Biopharmaceutical Industry Creates Value (And Jobs) for the U.S. Economy

In a recent piece for Forbes, Pfizer’s Chairman and CEO Ian Read highlights the significant …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

Greenwood: America Leads in Biopharmaceutical Innovation. Let’s Keep It That Way.

Writing last week for Morning Consult, BIO President and CEO Jim Greenwood proposed several policy …

Insurers Should Prevent Pharmacy Counter Sticker Shock, Not Encourage It

Sticker shock at the pharmacy counter is becoming increasingly more common for patients across the …

Insurers and PBMs Limit Access to Safer Opioid Alternatives

Opioid abuse and addiction in America continues to ravish communities, families, and individuals across the …

Debunking a Common Myth on Out-of-Pocket Costs

The facts continue to show that, when it comes to prescription drug costs, the country …

Four Questions for the Energy and Commerce Hearing on 340B

Later this morning, the House Energy and Commerce Committee will hold a hearing to examine …